CORAL GABLES, Fla.–(BUSINESS WIRE)–#Alpha1–AlphaNet, Inc., a not-for-profit specialty disease management
organization, has reached the $50 million level in contributions to the
Alpha-1 Foundation, according to AlphaNet President and CEO Robert C.
Alpha-1 Antitrypsin Deficiency, commonly known as “Alpha-1”, is a
genetic disorder causing life-threatening liver and/or lung disease.
Those diagnosed with the disorder refer to themselves as “Alphas.”
Founded in 1995, AlphaNet has consistently supported the Alpha-1
Foundation with funding for groundbreaking research efforts, as well as
specialized programs benefiting the Alpha-1 community. AlphaNet employs
a unique, patient-driven business model with the singular focus of
improving the lives of patients afflicted with Alpha-1.
“Through unique disease management partnerships, strong Board oversight
and rigorous fiscal controls, we have been able to consistently produce
excess revenues to support the Alpha-1 community,” explained Barrett.
AlphaNet serves more than 6,000 patients in the United States and Canada
with 56 Patient Service Coordinators located in 32 states and two
provinces. Over 85 percent of AlphaNet’s employees are Alphas.
A wide range of customized patient care, education and integrated
support services have been developed for Alpha-1 patients and the
medical professionals who treat them. Programs include a comprehensive
disease management program that has been documented to improve the
quality of life for those affected by Alpha-1. AlphaNet also initiates
research and supports pharmaceutical-sponsored clinical trials for
treatment of Alpha-1.
A majority of the members of the AlphaNet Board of Directors are Alphas.
Board members are geographically dispersed throughout the United States
and include: Robert C. Barrett – Florida, Bonnie J. Chakravorty, MSW,
PhD – Tennessee, Charles W. Frost – Virginia, Robert L. Greene, Jr. –
Michigan, Miekeleen D. Hart – Ohio, Ab Rees – Missouri, Robert A.
Sandhaus, MD, PhD – Colorado, and Grant M. Wood – Utah.
For more information, visit AlphaNet at http://www.alphanet.org/.
Alpha-1 Antitrypsin Deficiency (Alpha-1) is one of the most common
serious genetic disorders worldwide and is a leading reason for lung
transplantation in adults and liver transplantation among young
children. More than 120,000 Americans have the disorder, yet less than
10 percent have been accurately diagnosed. Researchers
estimate 20 million Americans are undetected carriers of the Alpha-1
gene and may be at risk.
Christine Lanser Yllanes, 305-648-9526